Natera (NASDAQ:NTRA) acquired full enrolment for the RenaCARE (Renasight Clinical Application, Review and Evaluation) study, which is a prospective, multi-center clinical trial to determine...
Through its university partnership, the firm wants to attract big pharma backers by making 100,000s of novel psychedelic derivatives for new precision medicine